Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Gains from Investment Securities (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Gains from Investment Securities for 5 consecutive years, with $166.0 as the latest value for Q3 2020.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $166.0 in Q3 2020 year-over-year; TTM through Sep 2020 was $166.0, a N/A change, with the full-year FY2018 number at $508000.0, down 24.96% from a year prior.
  • Gains from Investment Securities was $166.0 for Q3 2020 at Forte Biosciences, down from $335015.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $714000.0 in Q4 2017 to a low of -$916000.0 in Q1 2020.
  • A 5-year average of $62198.9 and a median of $30000.0 in 2016 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 1778.95% in 2017; the steepest drop was 2850.0% in 2017.
  • Forte Biosciences' Gains from Investment Securities stood at $38000.0 in 2016, then soared by 1778.95% to $714000.0 in 2017, then tumbled by 73.58% to $188651.0 in 2018, then changed by 0.0% to $188651.0 in 2019, then crashed by 99.91% to $166.0 in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Gains from Investment Securities are $166.0 (Q3 2020), $335015.0 (Q2 2020), and -$916000.0 (Q1 2020).